SCHEMBL6087746

SCHEMBL6087746

O=C1Nc2ccccc2C1=C1OCc2cc(NCCCl)ccc21

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 1/20 0.40
CCNA2 P20248 1/20 0.40
CDK2 P24941 1/20 0.40
CCNA1 P78396 1/20 0.40
MAOA P21397 1/20 0.35
ALK Q9UM73 4/20 0.35
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 1/20 0.34
PKM P14618 1/20 0.34
MAPT P10636 2/20 0.33
MAPK14 Q16539 1/20 0.33
PGR P06401 4/20 0.33
NR3C1 P04150 3/20 0.33
NR3C2 P08235 2/20 0.33
POLB P06746 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
TOP1 P11387 2/20 0.32
NPC1 O15118 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6087742 1.00 NTRK1 (0.40) NTRK1CCNA2CDK2CCNA1MAOA
SCHEMBL14715812 0.94 NTRK1 (0.39) NTRK1CCNA2CDK2CCNA1MAOA
SCHEMBL6086859 0.89 NTRK1 (0.42) NTRK1CCNA2CDK2CCNA1MAOA
SCHEMBL6086865 0.89 NTRK1 (0.42) NTRK1CCNA2CDK2CCNA1MAOA
SCHEMBL6086719 0.88 KDR (0.37) NTRK1KDM4EALDH1A1PKMPGR
SCHEMBL6086720 0.88 KDR (0.37) NTRK1KDM4EALDH1A1PKMPGR
SCHEMBL6087844 0.88 IMPDH2 (0.35) KDM4EALDH1A1PKMMAPK14PGR
SCHEMBL6087838 0.88 IMPDH2 (0.35) KDM4EALDH1A1PKMMAPK14PGR
SCHEMBL6089596 0.87 NTRK1 (0.41) NTRK1CCNA2CDK2CCNA1MAOA
SCHEMBL6089592 0.87 NTRK1 (0.41) NTRK1CCNA2CDK2CCNA1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490356-B1 (3Z)-3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN INC (US) 2013-02-27 EP disclosed
US-7060844-B2 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-06-13 US disclosed
US-20060004084-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-01-05 US disclosed
EP-1490356-A1 (3Z)-3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS Allergan, Inc. (US) 2004-12-29 EP disclosed
US-20040019098-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2004-01-29 US disclosed
WO-2003084951-A1 (3Z) -3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN, INC. (US) 2003-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004084-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors CDK2, ERBB2, MAP3K3 NTRK1 408/4885CCNA2 406/4885CDK2 1/4885
US-20040019098-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors CDK2, ERBB2, MAP3K3 NTRK1 420/4885CCNA2 423/4885CDK2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.